[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20090266L - Piperazinylderivater anvendelige i behandlingen av GPR38 receptormedierte sykdommer - Google Patents

Piperazinylderivater anvendelige i behandlingen av GPR38 receptormedierte sykdommer

Info

Publication number
NO20090266L
NO20090266L NO20090266A NO20090266A NO20090266L NO 20090266 L NO20090266 L NO 20090266L NO 20090266 A NO20090266 A NO 20090266A NO 20090266 A NO20090266 A NO 20090266A NO 20090266 L NO20090266 L NO 20090266L
Authority
NO
Norway
Prior art keywords
treatment
mediated diseases
derivatives useful
gpr38 receptor
piperazinyl derivatives
Prior art date
Application number
NO20090266A
Other languages
English (en)
Inventor
Mervyn Thompson
Susan Marie Westaway
Darren Jason Mitchell
Jonathan Thomas Seal
Samantha Louisa Brown
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38476358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20090266(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0612844A external-priority patent/GB0612844D0/en
Priority claimed from GB0711525A external-priority patent/GB0711525D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20090266L publication Critical patent/NO20090266L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Oppfinnelsen angår forbindelser med formel (I), fremgangsmåter for deres fremstilling, farmasøytiske sammensetninger som inneholder dem og deres anvendelse ved behandling av tilstander eller forstyrrelser som medieres via GPR38-reseptoren.
NO20090266A 2006-06-28 2009-01-16 Piperazinylderivater anvendelige i behandlingen av GPR38 receptormedierte sykdommer NO20090266L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0612844A GB0612844D0 (en) 2006-06-28 2006-06-28 Compounds
GB0711525A GB0711525D0 (en) 2007-06-14 2007-06-14 Compounds
PCT/EP2007/056342 WO2008000729A1 (en) 2006-06-28 2007-06-26 Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases

Publications (1)

Publication Number Publication Date
NO20090266L true NO20090266L (no) 2009-03-17

Family

ID=38476358

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090266A NO20090266L (no) 2006-06-28 2009-01-16 Piperazinylderivater anvendelige i behandlingen av GPR38 receptormedierte sykdommer

Country Status (30)

Country Link
US (2) US7700599B2 (no)
EP (1) EP2041093B1 (no)
JP (1) JP5028484B2 (no)
KR (1) KR20090031688A (no)
AR (1) AR061656A1 (no)
AT (1) ATE465150T1 (no)
AU (1) AU2007263712B2 (no)
BR (1) BRPI0713443A2 (no)
CA (1) CA2655540A1 (no)
CR (1) CR10497A (no)
CY (1) CY1110190T1 (no)
DE (1) DE602007006019D1 (no)
DK (1) DK2041093T3 (no)
EA (1) EA015820B1 (no)
ES (1) ES2344484T3 (no)
HK (1) HK1127608A1 (no)
HR (1) HRP20100284T1 (no)
IL (1) IL195900A0 (no)
JO (1) JO2645B1 (no)
MA (1) MA30539B1 (no)
MX (1) MX2009000110A (no)
MY (1) MY147677A (no)
NO (1) NO20090266L (no)
NZ (1) NZ573450A (no)
PE (1) PE20080345A1 (no)
PL (1) PL2041093T3 (no)
PT (1) PT2041093E (no)
SI (1) SI2041093T1 (no)
TW (1) TWI391386B (no)
WO (1) WO2008000729A1 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0611907D0 (en) 2006-06-15 2006-07-26 Glaxo Group Ltd Compounds
AU2006274212B2 (en) * 2005-07-26 2011-06-09 Glaxo Group Limited Benzylpiperazine derivates and their medical use
GB0524814D0 (en) * 2005-12-05 2006-01-11 Glaxo Group Ltd Compounds
ES2344484T3 (es) * 2006-06-28 2010-08-27 Glaxo Group Limited Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38.
GB0723317D0 (en) 2007-11-28 2008-01-09 Glaxo Group Ltd Compounds
JP5663743B2 (ja) * 2009-02-27 2015-02-04 ラクオリア創薬株式会社 モチリン受容体作動活性を有するオキシインドール誘導体
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
DK2623492T3 (da) * 2010-09-27 2014-08-11 Daiichi Sankyo Co Ltd Cyclohexanderivatforbindelse
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
SG11201807516UA (en) 2016-03-17 2018-09-27 Hoffmann La Roche 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar
CN116348461B (zh) * 2020-09-25 2024-08-06 上海美悦生物科技发展有限公司 一种嘧啶甲酰胺类化合物及其应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385912A (en) * 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
JPH06211886A (ja) 1992-11-04 1994-08-02 Chugai Pharmaceut Co Ltd エリスロマイシン誘導体
TW355711B (en) 1992-11-04 1999-04-11 Chugai Pharmaceutical Co Ltd Erythromycin derivatives
US5593994A (en) * 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
JP3901239B2 (ja) 1996-03-13 2007-04-04 大正製薬株式会社 アリールアルカン誘導体
US5965578A (en) * 1996-04-03 1999-10-12 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
DE19644195A1 (de) 1996-10-24 1998-04-30 Solvay Pharm Gmbh 10,13,15-Trioxatricyclo[9.2.1.1.·9·.·6·]-pentadecanon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
WO1998023629A1 (fr) * 1996-11-26 1998-06-04 Chugai Seiyaku Kabushiki Kaisha Composes de macrolides comportant une chaine a 13 elements, medicament les contenant et leur procede de preparation
US6060491A (en) * 1997-06-19 2000-05-09 Dupont Pharmaceuticals 6-membered aromatics as factor Xa inhibitors
US5972939A (en) * 1997-10-28 1999-10-26 Ortho-Mcneil Pharmaceutical, Inc. Cyclopentene derivatives useful as antagonists of the motilin receptor
DE19805822B4 (de) 1998-02-13 2009-02-05 Solvay Pharmaceuticals Gmbh 11-Acetyl-12,13-dioxabicyclo[8.2.1]tridecenon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US6165985A (en) 1998-02-13 2000-12-26 Solvay Pharmaceuticals Gmbh 11-acetyl-12,13-dioxabicyclo[8.2.1]-tridecenone derivatives, processes for their preparation and pharmaceutical compositions comprising them
GB9804734D0 (en) * 1998-03-05 1998-04-29 Pfizer Ltd Compounds
TR200102969T2 (tr) * 1999-04-15 2002-08-21 Bristol-Myers Squibb Company Siklik protein tirozin kinaz önleyicileri.
US20020052380A1 (en) * 2000-02-18 2002-05-02 Dinsmore Christopher J. Inhibitors of prenyl-protein transferase
US20020010184A1 (en) * 2000-02-18 2002-01-24 Dinsmore Christopher J. Inhibitors of prenyl-protein transferase
US6392040B2 (en) * 2000-03-13 2002-05-21 Ortho-Mcneil Pharmaceutical, Inc. Cyclopentene compounds useful as antagonists of the motilin receptor
WO2001068622A1 (en) * 2000-03-13 2001-09-20 Ortho-Mcneil Pharmaceutical, Inc. Novel cyclobutene derivatives useful as antagonists of the motilin receptor
US6423714B2 (en) * 2000-03-13 2002-07-23 Ortho Mcneil-Pharmaceutical, Inc.. Cyclohexene derivatives useful as antagonists of the motilin receptor
US6511980B2 (en) * 2000-05-05 2003-01-28 Ortho Mcneil Pharmaceutical, Inc. Substituted diamine derivatives useful as motilin antagonists
GB0013378D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Use of therapeutic benzamide derivatives
US7102009B2 (en) * 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US7105682B2 (en) * 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US6878714B2 (en) * 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
EP1392679B1 (de) 2001-05-10 2005-11-02 Solvay Pharmaceuticals GmbH Neue 1-amidomethylcarbonyl-piperidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US6977264B2 (en) * 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
GB0129015D0 (en) * 2001-12-04 2002-01-23 Glaxo Group Ltd Compounds
GB0129013D0 (en) * 2001-12-04 2002-01-23 Glaxo Group Ltd Compounds
SE0203302D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
US7223788B2 (en) * 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
US7338954B2 (en) 2003-09-17 2008-03-04 Bristol-Myers Squibb Company Compounds useful as motilin agonists and method
US7262195B2 (en) 2003-09-17 2007-08-28 Bristol-Myers Squibb Company Compounds useful as motilin agonists and method
BRPI0415051A (pt) * 2003-10-01 2006-11-28 Procter & Gamble compostos antagonistas do hormÈnio concentrador de melanina e suas composições farmacêuticas
WO2005063720A1 (ja) * 2003-12-25 2005-07-14 Nippon Shinyaku Co., Ltd. アミド誘導体及び医薬
WO2005077345A1 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
WO2005077368A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
US20050277629A1 (en) * 2004-03-18 2005-12-15 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
SE0401345D0 (sv) 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds: Pyridine as scaffold
GB0611907D0 (en) 2006-06-15 2006-07-26 Glaxo Group Ltd Compounds
US20080312209A1 (en) 2005-07-12 2008-12-18 Glaxo Group Limited Piperazine Heteroaryl Derivatives as Gpr38 Agonists
AU2006274212B2 (en) * 2005-07-26 2011-06-09 Glaxo Group Limited Benzylpiperazine derivates and their medical use
ES2344484T3 (es) * 2006-06-28 2010-08-27 Glaxo Group Limited Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38.

Also Published As

Publication number Publication date
EA015820B1 (ru) 2011-12-30
SI2041093T1 (sl) 2010-07-30
HK1127608A1 (en) 2009-10-02
EA200970065A1 (ru) 2009-06-30
PT2041093E (pt) 2010-06-28
MA30539B1 (fr) 2009-06-01
CR10497A (es) 2009-03-20
ATE465150T1 (de) 2010-05-15
JP2009541432A (ja) 2009-11-26
BRPI0713443A2 (pt) 2012-03-06
NZ573450A (en) 2011-11-25
JO2645B1 (en) 2012-06-17
MX2009000110A (es) 2009-01-23
HRP20100284T1 (hr) 2010-06-30
EP2041093B1 (en) 2010-04-21
MY147677A (en) 2012-12-31
AU2007263712A1 (en) 2008-01-03
JP5028484B2 (ja) 2012-09-19
PL2041093T3 (pl) 2010-09-30
AU2007263712B2 (en) 2012-08-30
KR20090031688A (ko) 2009-03-27
US7700599B2 (en) 2010-04-20
US20090192160A1 (en) 2009-07-30
TW200817352A (en) 2008-04-16
WO2008000729A1 (en) 2008-01-03
PE20080345A1 (es) 2008-05-29
AR061656A1 (es) 2008-09-10
DE602007006019D1 (de) 2010-06-02
US20080027065A1 (en) 2008-01-31
IL195900A0 (en) 2009-09-01
ES2344484T3 (es) 2010-08-27
CA2655540A1 (en) 2008-01-03
US8853218B2 (en) 2014-10-07
DK2041093T3 (da) 2010-08-02
TWI391386B (zh) 2013-04-01
CY1110190T1 (el) 2015-01-14
EP2041093A1 (en) 2009-04-01

Similar Documents

Publication Publication Date Title
NO20090266L (no) Piperazinylderivater anvendelige i behandlingen av GPR38 receptormedierte sykdommer
NO20070487L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20061743L (no) Kinazolinderivater
NO20081212L (no) Xantinderivater som selektive HM74A agonister
NO20066081L (no) Kinazolinderivater som erbB-reseptortyrosinkinaser
NO20083905L (no) Nye pyron-indol derivater og fremgangsmate for deres fremstilling
NO20071246L (no) Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
NO20082124L (no) Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom
NO20073876L (no) Pyrazolopyrimidinderivater som mGluR2-antagonister
NO20090628L (no) Pyridizinon derivativater
NO20084363L (no) 2-Substituerte 4-benzylftalazinonderivater som histamin H1- og H3-antagonister
NO20090267L (no) Substituerte N-fenylmetyl-5-okso-prolin-2-amider som P2X7-receptorantagonister og deres anvendelse
ATE542795T1 (de) Benzylpiperazinderivate als motilin- rezeptorantagonisten
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20070489L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20092342L (no) Azaspiroderivativater
NO20084747L (no) Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser
NO20084489L (no) Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet
NO20065678L (no) 3-(4-heteroarylcykloheksylamino) cyklopentankarboksamider som modulatorer for kjemokinreseptorer.
NO20082709L (no) Kjemiske forbindelser
NO20074258L (no) Pyridin-2-karboksamidderivater som MGLUR5 antagonister
NO20081844L (no) Terapeutiske forbindelser
NO20082496L (no) Pyrazinderivater
NO20081014L (no) Sammensetninger

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application